Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Kuerer on Eliminating Breast Cancer Surgery

January 25th 2017

Henry M. Kuerer, MD, PhD, professor of Surgery, The University of Texas MD Anderson Cancer Center, discusses the elimination of breast cancer surgery in exceptional responders.

Dr. Chang on Genomic Testing in Breast Cancer

January 25th 2017

Jenny C. Chang, MD, director of the Methodist Cancer Center at Houston Methodist Hospital, discusses genomic testing in breast cancer.

Dr. Tereffe on Treatment After Neoadjuvant Chemotherapy in Breast Cancer

January 24th 2017

Welela Tereffe, MD, associate professor, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, discusses the role of radiation therapy in the treatment of patients with breast cancer who previously received neoadjuvant chemotherapy.

Dr. Royce Reflects on Advances in HER2+ Breast Cancer

January 24th 2017

Melanie E. Royce, MD, PhD, co-director, Protocol Review and Monitoring System, member, Women’s Cancers Research Program, associate professor of Medicine, University of New Mexico Comprehensive Cancer Center, discusses some of the advancements in the field of HER2-positive breast cancer.

Dr. Abraham on Prevention of Hair Loss for Breast Cancer Chemotherapy

January 20th 2017

Jame Abraham, MD, director of the Breast Oncology Program at Taussig Cancer Institute, and co-director of the Cleveland Clinic Comprehensive Breast Cancer Program, discusses a head cooling system that can be used to limit hair loss attributed to chemotherapy treatment for patients with breast cancer.

Dr. Wolf Discusses the Videssa Breast Blood Test

January 20th 2017

Judith K. Wolf, MD, chief medical officer of Provista Diagnostics, discusses the capabilities of the blood-based diagnostic test Videssa Breast.

Dr. Sledge on Impact of CDK 4/6 Agents in Breast Cancer

January 19th 2017

George W. Sledge Jr., MD, professor of Medicine, Chief of the Division of Oncology, Stanford University Medical Center, discusses the use of cyclin-dependent kinase (CDK) 4/6 agents in the treatment of patients with breast cancer.

Dual HER2-Blockade Plus AI Shows Promise in HER2+/ER+ Breast Cancer

January 17th 2017

Data from the phase II PERTAIN trial presented late last year at the 2016 San Antonio Breast Cancer Symposium showed that adding an aromatase inhibitor (AI) to pertuzumab and trastuzumab extended progression-free survival by over 3 months versus trastuzumab plus an AI in patients with HER2-positive, HR-positive locally advanced or metastatic breast cancer.

Yardley Discusses Evolving Role of Nab-Paclitaxel in TNBC

January 16th 2017

Denise A. Yardley, MD, discusses the phase II tnAcity trial, the current role of nab-paclitaxel in triple-negative breast cancer, and the potential for using nab-paclitaxel in combination with immunotherapy in this setting.

Pegram Sheds Light on Margetuximab in HER2+ Breast Cancer

January 14th 2017

The Fc-modified monoclonal antibody margetuximab in combination with chemotherapy may offer a new treatment option for patients with HER2-positive metastatic breast cancer.

HER2 Vaccine Shows Promise in Early-Stage Breast Cancer

January 13th 2017

Anti-HER2 DC1 vaccination was demonstrated to be a safe and immunogenic treatment to induce tumor-specific T-cell responses in patients with HER2-positive breast cancer.

Dr. Yardley on tNACity Trial for Triple-Negative Breast Cancer

January 12th 2017

Denise Yardley, MD, senior investigator at the Sarah Cannon Research Institute, discusses the tNACity trial for patients with triple-negative breast cancer.

Veliparib Facing Phase III Test in BRCA-Positive Breast Cancer

January 12th 2017

Researchers are seeking to determine whether adding the PARP inhibitor veliparib to a chemotherapy combination will improve outcomes for patients with HER2-negative, germline BRCA-associated metastatic or locally advanced breast cancer.

Dr. Mamounas on Extended Letrozole Therapy for Breast Cancer

January 11th 2017

Eleftherios (Terry) P. Mamounas, MD, medical director of the Comprehensive Breast Program at the University of Florida Health Cancer Center, discusses the phase III trial for extended letrozole (Femara) therapy for patients with breast cancer.

Dr. Kalinsky on Ruxolitinib Plus Trastuzumab in HER2-Positive Breast Cancer

January 11th 2017

Kevin Kalinsky, MD, assistant professor of Medicine at Columbia University Medical Center, discusses a phase I study of ruxolitinib (Jakafi) in combination with trastuzumab (Herceptin) in metastatic HER2-positive breast cancer.

Samuel Smith on Adherence in Menopausal Women at Risk for Breast Cancer

January 11th 2017

Samuel Smith, PhD, university academic fellow at the University of Leeds, discusses a breast cancer prevention trial that measured adherence to preventative medication in women experiencing menopausal symptoms.

Dr. Soliman on Impact of MammaPrint in Patients With Early-Stage Breast Cancer

January 11th 2017

Hatem Soliman, MD, associate member of The Center for Women’s Oncology at the Moffitt Cancer Center discusses the prospective registry IMPACt study, which measured the impact of the MammaPrint 70-gene Breast Cancer Recurrence Assay in the routine management of women with early-stage breast cancer.

BRCA Gene Does Not Predict Poor Prognosis in Patients With Breast Cancer

January 10th 2017

While mutations of the BRCA gene can increase a woman’s chances of developing breast and ovarian cancers, the presence of the gene made no difference in survival for women aged 40 years or younger who were diagnosed with early-stage breast cancer.

Nab-Paclitaxel as Neoadjuvant Therapy for Breast Cancer

January 10th 2017

Yu (Amy) Zong, Shanghai Jiaotong University School of Medicine, discusses a meta-analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as neoadjuvant chemotherapy of breast cancer.

Dr. Montero Discusses PERTAIN Study in HER2-Positive Breast Cancer

January 9th 2017

Alberto J. Montero, MD, Department of Hematology and Oncology at Cleveland Clinic, discusses the PERTAIN study in postmenopausal women with hormone receptor-positive, HER2-positive, locally advanced or metastatic breast cancer. The study looks at the impact of adding pertuzumab (Perjeta) to trastuzumab (Herceptin) in aromatase inhibitor (AI) therapy.